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Abstract 
 
Background: Disturbances in the levels of one-carbon (1C) metabolism metabolites 
have been associated with a wide variety of neuropsychiatric diseases. CSF levels of 
Hcy and the other 1C metabolites, nor their interrelatedness and putative 
determinants, have been studied extensively in a healthy population. 
Methods: Plasma and CSF samples from 100 individuals free from neuropsychiatric 
diseases were analyzed (55 male, 45 female; age 50 ± 17 years). In blood, we 
measured plasma Hcy, serum folate and serum vitamin B12. In CSF, we measured 
total Hcy, SAM, SAH and 5-methylTHF. Highly selective analytical methods like liquid 
chromatography combined with either mass spectrometry or fluorescence detection 
were used. 
Results: CSF Hcy was inversely correlated with CSF 5-methylTHF and positively with 
plasma Hcy, independent of serum folate status. CSF SAH correlated with age, lower 
CSF 5-methylTHF, and higher CSF Hcy. CSF 5-methylTHF showed independent 
negative correlations with age, and positive correlations with serum folate. CSF SAM 
did not correlate with any of the 1C metabolites. 
Conclusions: Ageing is characterized by a reduction in CSF 5-methylTHF levels and 
increased CSF levels of the potentially neurotoxic transmethylation inhibitor SAH. 
CSF 5-methylTHF, which is itself determined in part by systemic folate status, is a 
powerful independent determinant of CSF levels of Hcy and SAH.
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Introduction 
 
One-carbon (1C) metabolism encompasses a series of biochemical reactions that 
involves the transfer of 1C moieties (Figure 1). One of its main purposes is to provide 
methyl groups for virtually all transmethylation reactions. 1C metabolism has been 
the focus of extensive research, particularly since increased plasma levels of one of 
its intermediates, homocysteine (Hcy), were linked to numerous diseases, such as 
cardiovascular disease (1) and neurological disease. (3,4). 
 
Studies with small sample sizes have also shown correlations of these neurological 
diseases with Hcy in cerebrospinal fluid (CSF).(5;6) To date, however, several 
uncertainties surround the association between increased plasma levels of Hcy and 
neuropsychiatric disease. Firstly, it is unclear whether plasma or CSF concentrations 
of these constituents are primarily of interest. In addition, it remains unclear whether 
Hcy itself or one of the other constituents of 1C metabolism exerts detrimental effects 
on the neural system. Potential candidates in this context include S-
adenosylmethionine (SAM), S-adenosylhomocysteine (SAH), and B-vitamin status. 
 
SAM is the methyl donor in many essential methylation reactions such as DNA 
methylation, synthesis and inactivation of neurotransmitters and myelin synthesis. 
SAH has opposite effects, in that it acts as a powerful inhibitor of most 
transmethylation reactions.(7) The SAM/SAH ratio has been used as a reflection of 
methylation potential in, amongst others, the central nervous system (CNS).(8) The 
potential relevance of SAM is supported by observations that low SAM levels in CSF 
are associated with depression and dementia.(9) The effect of SAH on 
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neuropsychiatric disturbances is less well studied. However, the CSF levels of SAH 
are associated with CSF levels of hyperphosphorylated tau, a marker for Alzheimer 
pathology (10). 
One-carbon metabolism is critically dependent on the B-vitamin status (B2, B6, B12 
and, predominantly, folate).(11) Deficiencies of B-vitamins are commonly seen in the 
elderly population.(12;13) Since the remethylation pathway via betaine is not 
expressed in the brain, the only option for remethylation of Hcy, and thus 
regeneration of methionine, is via 5-methyltetrahydrofolate (5-methylTHF; Figure 1). 
Therefore, low 5-methylTHF levels could not only increase Hcy levels but could also 
potentially diminish the methylation capacity of the brain.(14) Additionally, folates are 
involved in DNA synthesis, and low folate levels could potentially impair DNA stability 
and structure, for example by the misincorporation of uracil in DNA.(15) The literature 
on folate status as an independent risk factor for neuropsychiatric diseases indicates 
that low levels of 5-methylTHF in CSF are found in patients suffering from a wide 
spectrum of neuropsychiatric diseases such as Alzheimer, depression, and 
autism.(16-19) Additionally, the absence of 5-methylTHF in CSF in rare inborn errors 
of metabolism causes progressive neurological decline.(20) 
In short, concentrations in the CNS of Hcy, but also of other 1C metabolites, in 
particular SAM, SAH and 5-methylTHF, may be of relevance for the development of 
neuropsychiatric diseases. A better understanding of the determinants of these 
intermediates is important. This paper focuses on identification of determinants of 
Hcy, SAM, SAH and 5-methylTHF in CSF of individuals unaffected by 
neuropsychiatric disease. Additionally, the reference values in this paper will offer an 
indication for the sample size estimation of future studies. 
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Materials and methods 
 
Subjects 
Ninety eight subjects, who were subjected to a lumbar puncture (for different 
indications such as exclusion of CNS inflammation, exclusion of aneurysmal 
subarachnoid hemorrhage or exclusion of meningitis, all negative) at the Department 
of Neurology (University of Bonn), were enrolled in this study. Except for the 
symptoms they presented with – majorly acute, but not chronic cepahlgia – none of 
the enrolled subjects showed evidence or history of cognitive impairment or any other 
symptoms of possible neurological or psychiatric disease, which were exclusion 
criteria. Additional exclusion criteria for this study were: chronic or unstable medical 
illness (e.g. symptomatic cardiac disease, renal or hepatic dysfunction, insulin-
dependent diabetes mellitus, untreated thyroidal dysfunction), excessive alcohol 
intake, vitamin supplementation, disturbance of the blood brain-barrier (defined as 
CSF whole protein content >500mg/dL), or inflammation of the central nervous 
system (i.e. more than 5 leucocytes/mm3 or intrathecal immunglobuline production) 
or an abnormal result in the Mini Mental State Examination (MMSE), which was done 
for all subjects (21). The study was approved by the local ethics committee, and 
written informed consent was obtained from all study participants. 
 
Sample collection 
Diagnostic lumbar punctures were performed at the Department of Neurology, 
University of Bonn. A standardized technique with a 20G “atraumatical” spinal needle 
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and a sitting or lying position for the patient was applied. Approximately 10 to 14 ml of 
CSF was removed for analysis. Depending on the indication of the lumbar puncture, 
the first fractions were used for diagnostic purposes, the third or fourth for the current 
study. CSF samples were frozen immediately on dry ice.  
Fasting venous blood was collected in lithium heparine vacutainers, and immediately 
placed on ice. Plasma was isolated by centrifugation for 10 min at 2000 g at 4ºC. 
Light protected sera were used for the folate and vitamin B12 measurements which 
were centrifuged for 10 min at 3300 g at room temperature. All samples were stored 
at -80ºC until analysis. 
Methods 
Plasma total Hcy concentrations were determined by means of fully automated 
particle-enhanced immunonephelometry with a BN II System (Siemens Healthcare 
Diagnostics GmbH, Eschborn, Germany). The intraassay and interassay coefficient 
of variation (CV) of the homocysteine assay were 3.4% and 5.6 %, respectively. 
Serum vitamin B12 and folate concentrations were determined by means of a 
competitive chemiluminescent immunoassay with an Access™ Immunoassay 
System (Beckman Coulter, Krefeld, Germany). The intraassay and interassay CVs of 
the vitamin B12 assay were 3.8% and 6.3 %, respectively. The intraassay and 
interassay CVs of the folate assay were 2.8% and 4.8 %, respectively.  
CSF SAM and SAH concentrations were determined by LC-MS/MS (API3000, 
Applied Biosystems, Foster City, CA, USA). The intraassay and interassay CVs for 
SAM were 6.8% and 4.2%, respectively. The intraassay and interassay CVs for SAH 
were 6.9% and 5.5%, respectively.(22) 
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CSF folate vitamers were determined by LC-MS/MS (API3000, Applied Biosystems). 
Intraassay and interassay CVs for 5-methyltetrahydrofolate (5-methylTHF) were 1.2% 
and 2.8%, respectively. Intraassay and interassay CVs for non-methylTHF as a group 
were 1.6% and 1.5%, respectively.(23) 
CSF total Hcy concentrations were measured by HPLC using fluorescence detection 
(Waters, Milford, MA, USA). An adaptation of a previously published method was 
used.(24) In order to be able to measure the nanomolar homocysteine concentration 
in 100 µL of CSF accurately, the reaction volume was minimized, and a flushing 
gradient (30% acetonitrile) was added after each injection to create a more stable 
HPLC baseline. The intraassay and interassay CVs were 2.2% and 3.6% 
respectively.  
 
Statistical analysis 
All statistical analyses were performed using SPSS 17.0 for Windows. Most of the 
measured parameters showed positively skewed distributions (plasma Hcy, CSF 
Hcy, serum folate, serum B12, CSF SAH, CSF SAM/SAH), so the data were log 
transformed prior to regression analysis. As outlined in the introduction, the main 
dependent variables of interest in CSF were Hcy, SAM, SAH, SAM/SAH and 5-
methylTHF. We performed separate analyses to identify determinants of these CSF 
constituents. 
In order to reduce the risk of finding associations by chance, a priori hypotheses 
regarding plausible determinants of the dependent variables of interest were 
formulated using available knowledge of 1C metabolism and epidemiology. For CSF 
Hcy, we first assessed traditional determinants known to influence plasma Hcy, 
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namely age and B-vitamin status (in both plasma and CSF). In order to determine 
whether serum folate status would determine CSF Hcy via its correlation with CSF 
folate status, serum folate and CSF 5-methylTHF were analyzed in a multiple 
regression model. In addition, we analyzed the correlation between plasma versus 
CSF Hcy, and adjusted associations between serum folate status and CSF Hcy for 
plasma Hcy. All significant determinants of CSF Hcy were finally entered into a single 
multiple regression model. 
For CSF SAM, SAH and their ratio, the following potential determinants were 
analyzed: age, serum B vitamin status, plasma and CSF Hcy, and CSF 5-methylTHF. 
Positive correlations were analyzed for independence, again with multiple regression 
analysis 
Finally, for CSF 5-methylTHF, we assessed whether its concentration independently 
correlated with age and/or serum folate status, and whether the CSF 5-
methylTHF/serum folate ratio correlated with age.  
Since most of the measured parameters were log transformed, interpretation of the 
effect size of a given determinant on the investigated 1C metabolite is difficult. In 
order to display the effect sizes more clearly, we divided the non logarithmic 
transformed levels of the investigated metabolites into tertiles, repeated the 
multivariate analyses, and plotted the increase in the dependent variable in tertiles, 
with the first tertile as reference. 
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Results 
 
Characteristics of included individuals are listed in Table1. CSF values for Hcy, 
folate, SAM, and SAH compared well with a previous reported study.(8) Some 
individuals showed hyperhomocysteinemia in plasma, which coincided with low 
serum folate levels. Subjects were not excluded for this reason. With regard to the 
comparison of 1C metabolites levels in CSF to plasma, CSF Hcy levels were a 100 
fold lower than the plasma levels. Remarkably, CSF folate levels were substantially 
higher than plasma levels. SAM and SAH levels in CSF were comparable to plasma 
levels, previously determined using similar analytical methods.(25) Of note, folate 
existed in CSF predominantly in the 5-methylTHF form, as was previously described 
for plasma.(26) With regard to gender, no significant correlations with any of the 
parameters were found (data not shown). 
 
Determinants of CSF Hcy 
For the potential determinants of CSF Hcy listed in the methods section, the 
univariate correlations were determined. The results are listed in Table 2. CSF Hcy 
levels were positively correlated with plasma Hcy and CSF SAH, and negatively 
correlated with serum folate and CSF folate. Age, a traditional determinant of plasma 
Hcy, just failed to reach significance for CSF Hcy (P=0.075).  
Multiple regression analysis was used to determine interdependence of the univariate 
correlations. As is evident from both multivariate regression model 1 and 2 in Table 2, 
serum folate is not an independent determinant of CSF Hcy. Rather, its correlation 
with CSF Hcy is predominantly explained by its effect on CSF 5-methylTHF and 
plasma Hcy. 
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As explained in Figure 1, the metabolic fate of Hcy is determined by several 
pathways, implying that its concentration could be independently correlated to 
parameters related to these pathways. Regression model 3 indeed identified CSF 5-
methylTHF (remethylation), plasma Hcy (import/export across the blood-brain barrier) 
and CSF SAH (SAH hydrolase activity) as independent determinants of CSF Hcy 
levels. When age and vitamin B12 were forced into the multiple regression model, 
they were again not significantly related to CSF Hcy (data not shown). The Figure 2 
demonstrates the multiple adjusted impact of plasma Hcy, CSF 5-methylTHF, and 
CSF SAH on CSF Hcy. 
  
Determinants of CSF SAM, SAH and SAM/SAH 
As shown in Table 3, CSF SAM showed no significant correlation with any of the 
potential determinants studied. CSF SAH was independently positively correlated 
with age and CSF Hcy, and negatively correlated with CSF 5-methylTHF (Figure 2). 
The CSF SAM/SAH ratio was independently positively correlated with CSF 5-
methylTHF and negatively correlated with age and CSF Hcy. None of the serum 
parameters (Hcy, folate and B12) showed any significant correlation with either CSF 
SAM, SAH or the SAM/SAH ratio (data not shown). 
 
Determinants of CSF 5-methylTHF 
As shown in Table 4, CSF 5-methylTHF is negatively correlated with age and 
positively correlated with serum folate concentrations. A multivariate regression 
model for both age and serum folate was applied, showing that both parameters 
independently influence CSF 5-methylTHF (Figure 2). Additionally, the ratio CSF 5-
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methylTHF/serum folate was negatively correlated with age (R2=0.076, ß=-0.276, 
P=0.008). 
 
Discussion 
  
The salient findings of our study in healthy individuals are that, firstly, older age and 
lower serum folate status are independently associated with lower CSF 5-methylTHF 
availability. This may be unfavorable, since we also observed that a low CSF folate 
status adversely affects CSF Hcy and methylation potential, at least insofar as the 
latter is reflected by concentrations of SAH. Secondly, aging also appears to directly 
adversely affect methylation potential, independent of CSF folate status. Finally, CSF 
Hcy appears to be at least partly determined by plasma Hcy, suggesting a degree of 
blood-brain equilibration. In the highest tertile of CSF Hcy, the contribution of plasma 
Hcy is less, suggesting that higher CSF Hcy is predominantly related to intracerebral 
metabolism, rather than to equilibration with plasma Hcy. CSF Hcy is independently 
correlated to the concentration of the transmethylation inhibitor SAH, which may 
represent a mechanism of untoward effects of CSF Hcy. 
The fate of Hcy in CSF will depend on many different factors (remethylation, export 
from brain tissue, transport across the blood-brain barrier, equilibrium with SAH, etc). 
From the perspective of Hcy metabolism (Figure 1), the positive correlation of CSF 
Hcy with both plasma Hcy and CSF SAH, and the negative correlation with CSF 5-
methylTHF seems logical. (8)  However, given the strong degree of inter-relatedness 
of 1C metabolites, analyzing statistical independency of these associations, as we 
did in the current study, is crucial.   
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The methylation potential of cells is conceivably reflected by SAM and SAH (and their 
ratio), since SAM is a universal methyl donor, and SAH is an inhibitor of most 
transmethylation reactions. However, in line with previously reported data, CSF SAM 
levels did not correlate with any of the other studied potential determinants.(8) From 
a teleological perspective, this could mean that keeping CSF SAM levels stable is 
vitally important, which would be in keeping with its central role not only as a methyl 
donor, but also as a regulator of enzyme activity in both the remethylation and 
transsulfuration pathway. The fact that significantly lower amounts of SAM were 
measured in CSF of patients suffering from depression and dementia, may offer 
insight into how disturbances in 1C metabolism and this type of diseases are 
linked.(9) It may be that intracellular concentrations in brain tissue obtained from 
specific regions will offer more insight into these matters, since CSF SAM does not 
correlate well with intracellular SAM concentrations in brain.(27;28) 
Levels of the methyltransferase inhibitor SAH were adversely associated with higher 
age and CSF Hcy.(8) Age seems to be a strong determinant of the methylation 
potential in the brain. The underlying mechanism remains unclear. 
 
In our study, CSF folate levels were approximately 5 times higher than serum folate 
levels. Another study (17) showed similar results, while a further one (8) observed 
higher folate serum levels than in our population, and lower CSF levels. However, 
this last study did not use multivitamin intake as a exclusion criteria. This may 
account for the higher plasma values. Perhaps folate demand in the brain is higher 
than in other organs, but exactly how the brain maintains its high folate status is 
mechanistically unknown. The relation between increased age and diminished serum 
folate levels has been well documented.(13) This correlation has been attributed to 
13 
the decreased ability for folate uptake in the elderly population (12;13) Our study also 
showed that age was an independent determinant of CSF folate levels, a fact that 
has not been described before to our knowledge.  
Since, CSF folate levels have been shown not to follow serum folate levels outside 
the normal range (≥ 45 nmol/L)(8), an additional determinant of CSF folate is of 
importance. Choroid plexus epithelial cells express high levels of folate 
receptor α suggesting that a role for it in folate trafficking.(29) Perhaps transport of 
folate over the blood-brain barrier is also a determinant of CSF folate, and might be 
the rate limiting step. The observation that the CSF/serum folate ratio diminishes with 
age may suggest that this transport alters with age. Supplementation might increase 
the often reduced plasma folate levels of the elderly. However, whether this 
supplementation will lead to desired increase in CSF folate has yet to be determined. 
Additionally, this observation of hindered transport of folate across the blood-brain 
barrier could provide insight to the origin of the low CSF folate levels observed in 
cerebral folate deficiency, a treatable neurological abnormality with genetic, acquired 
or even unknown etiology. (30) Whether deficient CSF folate reflects an intracellular 
folate deficiency in the brain is not well understood. Because of the strong observed 
correlation between CSF folate and CSF Hcy, CSF Hcy could be considered to be a 
more practical biomarker (compound stability) of cerebral folate deficiency.  
Obtaining CSF samples from healthy volunteers is difficult. Even though individuals 
taking medication or suffering from diseases known to influence the 1C metabolism 
were omitted, a certain degree of bias cannot be excluded. 
Having identified the determinants of 1C metabolites in CSF, it will be interesting to 
investigate whether the same determinants play a role in various neurodegenerative 
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diseases, and whether various intervention strategies can alter CSF concentrations 
of the relevant 1C metabolites, offering pathways to prevention and/or treatment. 
In conclusion, CSF 5-methylTHF levels decrease while CSF SAH levels increase with 
age, which may contribute to CNS ageing and neurodegeneration. Higher serum 
folate concentrations were associated with higher CSF concentrations of 5-
methylTHF and with lower levels of the neurotoxic agents Hcy and SAH arguing that 
folate deficiency may accelerate ageing and neurodegeneration. 
15 
Table 1: Study population characteristics (data are presented as mean (SD) or, 
in case of skewed distributions, as median (range)). 
Age, years 50 ± 17 
Gender, male/female, n 55/45 
Plasma homocysteine, µM 11 (4-34) 
Serum total folate, nM 11 (2-39) 
Serum vitamin B12, pg/mL 325 ± 126 
CSF homocysteine, nM 61 (13-303) 
CSF 5-methylTHF, nM 42 ± 14 
CSF non-methylTHF, nM 0 (0-12) 
% non-methylTHF 0 (0-31) 
CSF SAM, nM 205 ± 41 
CSF SAH, nM 22 (11-49) 
CSF SAM/SAH 9 (3-20) 
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Table 2: Univariate and multivariate regression models of determinants of CSF 
Hcy. 
 
 
Regression type Dependent Independent β P 
Univariate CSF Hcyc Age 0.181 0.075 
Univariate CSF Hcyc CSF 5-methylTHF -0.495 0.000b 
Univariate CSF Hcyc Plasma Hcyc 0.331 0.001b 
Univariate CSF Hcyc Serum folatec -0.244 0.019a 
Univariate CSF Hcyc Serum B12c -0.176 0.094 
Univariate CSF Hcyc CSF SAHc 0.380 0.000b 
Multivariate 1 CSF Hcyc CSF 5-methylTHF -0.499 0.000b 
  Serum folatec 0.008 0.943 
Multivariate 2 CSF Hcyc Plasma Hcyc 0.279 0.016a 
  Serum folatec -0.109 0.339 
Multivariate 3 CSF Hcyc CSF 5-methylTHF -0.338 0.001b 
  Plasma Hcyc 0.204 0.027a 
  CSF SAHc 0.265 0.004b 
a Correlation is significant at the 0.05 level (2-tailed), b Correlation is significant at the 
0.01 level (2-tailed), c Log transformed data. 
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Table 3: Univariate and multivariate regression models of determinants of CSF 
SAM, SAH and SAM/SAH. 
 
Regression type Dependent Independent β P 
Univariate CSF SAM Age 0.033 0.750 
Univariate CSF SAM CSF 5-methylTHF 0.093 0.365 
Univariate CSF SAM CSF Hcyc 0.164 0.107 
Univariate CSF SAHc Age 0.462 0.000b 
Univariate CSF SAHc CSF 5-methylTHF -0.321 0.001b 
Univariate CSF SAHc CSF Hcyc 0.380 0.000b 
Univariate CSF SAM/SAHc Age -0.405 0.000b 
Univariate CSF SAM/SAHc CSF 5-methylTHF 0.361 0.000b 
Univariate CSF SAM/SAHc CSF Hcyc -0.252 0.012a 
Multivariate CSF SAH Age 0.391 0.000b 
  CSF 5-methylTHF -0.097 0.336 
  CSF Hcyc 0.261 0.010a 
Multivariate CSF SAM/SAH Age -0.333 0.001b 
  CSF 5-methylTHF 0.246 0.022a 
  CSF Hcyc -0.070 0.499 
a Correlation is significant at the 0.05 level (2-tailed), b Correlation is significant at the 
0.01 level (2-tailed), c Log transformed data. All serum (Hcy, folate and B12) 
correlations were not significant. 
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Table 4: Univariate and multivariate regression models of determinants of CSF 
5-methylTHF. 
 
Regression type Dependent Independent β P 
Univariate CSF 5-methylTHF Age -0.242 0.016a 
Univariate CSF 5-methylTHF Serum folatec 0.504 0.000b 
Multivariate CSF 5-methylTHF Age -0.256 0.004b 
  Serum folatec 0.511 0.000b 
a Correlation is significant at the 0.05 level (2-tailed), b Correlation is significant at the 
0.01 level (2-tailed), c Log transformed data. 
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Figure legends 
 
 
Figure 1: Overview of the 1 carbon metabolic pathway in humans. Homocysteine 
(Hcy) can follow two pathways. It could be remethylated to methionine, and 
subsequently converted to the universal methyl donor S-adenosylmethionine (SAM). 
Disturbed remethylation influences methylation reactions such as the methylation of 
neurotransmitters or DNA. Alternatively, Hcy can be irreversibly converted to 
cystathionine and further to cysteine. However, whether this transsulfuration pathway 
is active in the brain, is still debated. (31) Elevated Hcy levels could also influence 
SAH levels by the equilibrium reaction. High SAH is an inhibitor of a wide variety of 
methyltransferases. (32)  
(methionine synthase (MS), methylene tetrahydrofolate reductase (MTHFR),  
cystathionine β-synthase (CBS), methionine adenosyl transferase (MAT), SAH 
hydrolase (SH)). 
 
Figure 2: Change in CSF Hcy, CSF Folate, and CSF SAH  in respective tertiles 
(multivariate regression model). Effect sizes were adjusted for the variables as 
indicated in Table 2. 
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